Reviva Pharmaceuticals (RVPH) Competitors $0.73 -0.05 (-6.88%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$0.75 +0.03 (+3.54%) As of 06/13/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RVPH vs. PBYI, NLTX, SLS, ALTS, LFVN, PRME, ACOG, ACRS, ALMS, and SPROShould you be buying Reviva Pharmaceuticals stock or one of its competitors? The main competitors of Reviva Pharmaceuticals include Puma Biotechnology (PBYI), Neoleukin Therapeutics (NLTX), SELLAS Life Sciences Group (SLS), Janone (ALTS), LifeVantage (LFVN), Prime Medicine (PRME), Alpha Cognition (ACOG), Aclaris Therapeutics (ACRS), Alumis (ALMS), and Spero Therapeutics (SPRO). These companies are all part of the "pharmaceutical products" industry. Reviva Pharmaceuticals vs. Its Competitors Puma Biotechnology Neoleukin Therapeutics SELLAS Life Sciences Group Janone LifeVantage Prime Medicine Alpha Cognition Aclaris Therapeutics Alumis Spero Therapeutics Reviva Pharmaceuticals (NASDAQ:RVPH) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability. Which has stronger valuation & earnings, RVPH or PBYI? Puma Biotechnology has higher revenue and earnings than Reviva Pharmaceuticals. Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReviva PharmaceuticalsN/AN/A-$39.26M-$0.79-0.92Puma Biotechnology$232.71M0.71$21.59M$0.774.35 Does the MarketBeat Community prefer RVPH or PBYI? Puma Biotechnology received 528 more outperform votes than Reviva Pharmaceuticals when rated by MarketBeat users. However, 91.18% of users gave Reviva Pharmaceuticals an outperform vote while only 67.43% of users gave Puma Biotechnology an outperform vote. CompanyUnderperformOutperformReviva PharmaceuticalsOutperform Votes3191.18% Underperform Votes38.82%Puma BiotechnologyOutperform Votes55967.43% Underperform Votes27032.57% Do analysts recommend RVPH or PBYI? Reviva Pharmaceuticals presently has a consensus price target of $9.00, indicating a potential upside of 1,139.16%. Puma Biotechnology has a consensus price target of $7.00, indicating a potential upside of 108.96%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Reviva Pharmaceuticals is more favorable than Puma Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Reviva Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Puma Biotechnology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, RVPH or PBYI? Reviva Pharmaceuticals has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Do institutionals & insiders hold more shares of RVPH or PBYI? 63.2% of Reviva Pharmaceuticals shares are held by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are held by institutional investors. 27.2% of Reviva Pharmaceuticals shares are held by insiders. Comparatively, 23.3% of Puma Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is RVPH or PBYI more profitable? Puma Biotechnology has a net margin of 9.56% compared to Reviva Pharmaceuticals' net margin of 0.00%. Puma Biotechnology's return on equity of 41.60% beat Reviva Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Reviva PharmaceuticalsN/A N/A -252.53% Puma Biotechnology 9.56%41.60%10.71% Does the media prefer RVPH or PBYI? In the previous week, Puma Biotechnology had 1 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 3 mentions for Puma Biotechnology and 2 mentions for Reviva Pharmaceuticals. Puma Biotechnology's average media sentiment score of 1.36 beat Reviva Pharmaceuticals' score of 0.93 indicating that Puma Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Reviva Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Puma Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryPuma Biotechnology beats Reviva Pharmaceuticals on 11 of the 18 factors compared between the two stocks. Get Reviva Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RVPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RVPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RVPH vs. The Competition Export to ExcelMetricReviva PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$33.95M$6.88B$5.57B$8.51BDividend YieldN/A2.51%5.27%4.15%P/E Ratio-0.658.4626.7519.65Price / SalesN/A262.48404.17152.18Price / CashN/A65.8538.2534.64Price / Book3.636.526.964.59Net Income-$39.26M$143.26M$3.23B$248.23M7 Day Performance-11.59%-0.21%-1.22%-1.07%1 Month Performance-13.43%10.62%6.34%2.59%1 Year Performance-50.25%3.63%33.05%13.50% Reviva Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RVPHReviva Pharmaceuticals2.7238 of 5 stars$0.73-6.9%$9.00+1,139.2%-50.3%$33.95MN/A-0.655News CoveragePBYIPuma Biotechnology4.0878 of 5 stars$3.29+0.3%$7.00+112.8%+7.7%$163.29M$232.71M6.85200NLTXNeoleukin TherapeuticsN/A$17.01-9.2%N/A-53.6%$159.86MN/A-5.4790Gap DownHigh Trading VolumeSLSSELLAS Life Sciences Group0.3688 of 5 stars$1.58-7.6%N/A+10.7%$157.65M$1M-2.2910News CoveragePositive NewsShort Interest ↑High Trading VolumeALTSJanoneN/A$9.01-3.2%N/AN/A$157.27M$18.05M0.00170Short Interest ↑Gap DownLFVNLifeVantage3.9842 of 5 stars$12.45-4.6%$30.50+145.0%+80.1%$156.72M$222.35M22.23260Positive NewsPRMEPrime Medicine4.0033 of 5 stars$1.19+0.8%$10.08+747.3%-79.5%$156.24M$3.85M-0.58234Positive NewsACOGAlpha Cognition1.7614 of 5 stars$9.74+4.4%$20.00+105.3%N/A$156.04M$2.93M-3.80N/ANews CoverageGap UpACRSAclaris Therapeutics2.6658 of 5 stars$1.44-1.4%$9.71+574.6%+24.6%$155.93M$17.78M-2.77100Positive NewsALMSAlumis2.8537 of 5 stars$3.29-6.0%$24.86+655.5%N/A$155.36M$17.39M0.00N/APositive NewsUpcoming EarningsAnalyst UpgradeAnalyst RevisionHigh Trading VolumeSPROSpero Therapeutics3.8111 of 5 stars$2.74+9.6%$5.00+82.5%+108.1%$153.20M$28.30M39.15150Short Interest ↑Gap DownHigh Trading Volume Related Companies and Tools Related Companies PBYI Alternatives NLTX Alternatives SLS Alternatives ALTS Alternatives LFVN Alternatives PRME Alternatives ACOG Alternatives ACRS Alternatives ALMS Alternatives SPRO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RVPH) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reviva Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Reviva Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
